Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITAET DUISBURG-ESSEN is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners and a matching number of art units. BOECKELMAN, JACOB A is the busiest examiner, currently responsible for 1 pending action.
The distribution across those art units suggests that the matters cover different sub-fields within Biotechnology & Pharmaceuticals. Because each action is assigned to a different one of the 2 distinct examiners, the university must navigate two separate examination processes. This lack of overlap between the examiners and units requires a tailored strategy for each application.
Practitioners should note that with those matters and those examiners, there is no centralization of the prosecution effort. The involvement of those units further diversifies the potential challenges and prior art that may be encountered. This structure ensures that the outcome of one matter is independent of the other. BOECKELMAN, JACOB A manages 1 pending action, representing half of the current portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684552 | A BIOMARKER INDICATING THE THERAPEUTIC EFFICACY OF EXTRACELLULAR VESICLE (EV)- PREPARATIONS | BOECKELMAN, JACOB A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684552 | A BIOMARKER INDICATING THE THERAPEUTIC EFFICACY OF EXTRACELLULAR VESICLE (EV)- PREPARATIONS | BOECKELMAN, JACOB A | — |
| 18568474 | METHOD FOR IMMORTALISING VESICLE-SECRETING CELLS | BERTOGLIO, VALARIE E | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684552 | A BIOMARKER INDICATING THE THERAPEUTIC EFFICACY OF EXTRACELLULAR VESICLE (EV)- PREPARATIONS | BOECKELMAN, JACOB A | 1655 | §102§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18568474 | METHOD FOR IMMORTALISING VESICLE-SECRETING CELLS | BERTOGLIO, VALARIE E | 1632 | §102Other | Non-Final OA | — | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial